3 research outputs found

    Alterations of Erythrocyte Superoxide Dismutase activity in patients suffering from asthma attacks

    Get PDF
    Background. Oxidant-antioxidant imbalance may play an important role in the development and progression of bronchial asthma. However, the role of blood antioxidants especially in asthma exacerbation has not been fully discussed. Objective. This study examines a part of the intracellular antioxidant defense mechanism in asthmatic patients admitted to hospital due to severe exacerbation of their disease. Methods. Peripheral blood Erythrocyte Superoxide Dismutase (SOD) activity was measured in 38 patients (33 men - 5 women, with a mean age of 56±2.8 yrs), using a colorimetric method. On the days of admission and discharge the Forced Expiratory Volume in 1 second (FEV1) and the Partial arterial Oxygen pressure (PaO2) were recorded and correlated with SOD activity at the same time. Results. A statistically significant decrease of SOD activity was observed on the day of admission compared to SOD activity on the day of discharge (43.64±31.78 vs. 96.16±54.05 units/ml, p<0.001), suggesting the presence of oxidative stress during an asthma attack. A statistically significant correlation was observed between FEV1 on admission and SOD activity at the same time (r=0.57, p<0.001). Furthermore, SOD activity on admission was correlated with PaO2 on discharge (r=0.55, p<0.001), as well as SOD on discharge with PaO2 on discharge (r=0.53, p=0.001). Conclusions. Decreased systemic erythrocyte SOD activity was observed during asthma attacks. This activity was correlated with severity criteria such as FEV1 and PaO2. Therefore, it seems that measurement of SOD activity could be a useful tool in the evaluation of an asthma attack. The supplementary administration of antioxidants in the future needs further clarification

    Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial

    No full text
    Background: Retinopathy of prematurity (ROP) eye examination screening presupposes adequate mydriasis for an informative fundoscopy of preterm infants at risk, on a weekly basis. Systemic absorption of the instilled mydriatic regimens has been associated with various adverse events in this fragile population. This report aims to present the fully developed protocol of a full-scale trial for testing the hypothesis that the reduced mydriatic drop volume achieves adequate mydriasis while minimizing systemic adverse events. Methods: A non-inferiority crossover randomized controlled trial will be performed to study the efficacy and safety of combined phenylephrine 1.67% and tropicamide 0.33% microdrops compared with standard drops in a total of 93 preterm infants requiring ROP screening. Primary outcome will be the pupil diameter at 45 (T45) min after instillation. Pupil diameter at T90 and T120 will constitute secondary efficacy endpoints. Mixed-effects linear regression models will be developed, and the 95% confidence interval approach will be used for assessing non-inferiority. Whole blood samples will be analyzed using hydrophilic liquid chromatography–tandem mass spectrometry method (HILIC–MS/MS), for gathering pharmacokinetic (PK) data on the instilled phenylephrine, at nine specific time points within 3 h from mydriasis. Pooled PK data will be used due to ethical restrictions on having a full PK profile per infant. Heart rate, oxygen saturation, blood pressure measurements, and 48-h adverse events will also be recorded. Discussion: This protocol is designed for a study powered to assess non-inferiority of microdrops compared with standard dilating drops. If our hypothesis is confirmed, microdrops may become a useful tool in ROP screening. Trial registration: ClinicalTrials.govNCT05043077. Registered on 2 September 2021 © 2022, The Author(s)

    Central line-associated bloodstream infections in pediatric patients: Results from a national nosocomial infections surveillance program

    No full text
    ΟBJECTIVE To provide updated data on the rates of central line-associated bloodstream infections (CLABSI) in Greek neonatal intensive care units (NICUs), pediatric intensive care units (PICUs) and pediatric oncology units (PONCs), and to describe pathogen distribution and antimicrobial resistance patterns for CLABSIs. METHOD Active surveillance for CLABSI was conducted from June 2016 to December 2019 (43 months). A consortium of 14 NICUs, 3 PICUs, and 6 PONCs participated in the program. Surveillance definitions of central line (CL), central line utilization (CLU) ratio, CLABSI event, and CLABSI rate were based on the 2014 National Healthcare Safety Network criteria of the US Centers for Disease Control and Prevention (CDC). Medical records were assessed daily for calculation of CL-days, pa-tient-days, and susceptibility to isolated organisms. RESULTS A total of 519 CLABSI episodes were recorded in the 43 months. Mean CLABSI rates were 7.15 in NICUs, 5.19 in PICUs, and 2.20, per 1,000 CL-days in PONCs. A higher mean CLU ratio was reported in PONCs (0.83) and a lower mean ratio was found in NICUs (0.15). A total of 567 pathogens were isolated, the most common of which were Enterobacterales (42.1%), followed by Gram-positive cocci (29%), non-fermenting Gram-negative bacteria (14.6%), and fungi (11.5%). Among 239 (63.1%) Enterobacterales isolated, 151 were multidrug resistant. Overall, 14.8% of Gram-negative pathogens were resistant to third generation ceph-alosporins and 23.7% to carbapenems. CONCLUSIONS The rates of CLABSI and antibiotic resistance among organ-isms causing CLABSI are high in high-risk hospitalized children. These data highlight the significance of this problem and emphasize the need for implementation of infection prevention interventions. The methodology used for this surveillance program could be applied in other pediatric or adult units across Greece. © Athens Medical Society
    corecore